February 2019—Insight Genetics launched its proprietary Insight TNBCtype, a test for categorizing triple-negative breast cancer tumors into distinct molecular subtypes through its wholly owned CLIA- and CAP-accredited laboratory, Insight Molecular Labs. Insight TNBCtype is a CLIA-validated assay for TNBC molecular subtyping that will enable prospective clinical trials with pharmaceutical, biotechnology, and academic medical institutions and advance targeted therapies for TNBC patients. The test is based on a proprietary algorithm that uses gene expression data from next-generation sequencing to generate five molecular subtypes (BL1, BL2, LAR, MSL, and M) as well as a complementary immunomodulatory classifier that may help predict response to immuno-oncology therapies.
Insight Genetics, 615-255-8880